|Dr. Severin Schwan||CEO & Exec. Director||7.06M||N/A||1967|
|Dr. Alan Hippe||Chief Financial & Information Officer||4.02M||N/A||1967|
|Ms. Cristina A. Wilbur||Chief People Officer||2.65M||N/A||1967|
|Mr. Thomas Schinecker||Chief Exec. Officer of Roche Diagnostics||2.57M||N/A||1975|
|Mr. William N. Anderson||Chief Exec. Officer of Roche Pharmaceuticals||5.66M||N/A||1966|
|Dr. Karl Mahler||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Claudia Boeckstiegel||Gen. Counsel||N/A||N/A||1964|
|Ms. Pascale Schmidt||Chief Compliance Officer||N/A||N/A||1973|
|Mr. Nicolas Dunant||Head of Group Media Relations||N/A||N/A||N/A|
|Ehab Yousef||Head of Middle East Sub-Region 1||N/A||N/A||N/A|
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG’s ISS governance QualityScore as of 30 April 2021 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 1; Compensation: 8.